Sign Up
Stories
Advancements in Lymphoma Treatments
Share
Advancements in Cancer Treatment and Mar...
AnaMar Receives Orphan Drug Designation ...
Autolus Thrives with $350M Offering and ...
ADC Therapeutics Reports Financial Progr...
ADC Therapeutics Webcast Announced
AI-Powered Cancer Drug Trials
Overview
API
Advancements in lymphoma treatments: Scenic Biotech's SC-2882 shows promise as a potential new therapeutic approach for diffuse large B-cell lymphoma (DLBCL), while Genmab and AbbVie's bispecific antibody epcoritamab demonstrates high overall and complete response rates in patients with relapsed/refractory follicular lymphoma (FL).
Ask a question
How do these advancements in lymphoma treatments reflect the ongoing efforts to improve therapies for cancer patients?
How might the potential new therapeutic approach for DLBCL impact the current treatment landscape for this lymphoma type?
What are the potential implications of the high overall and complete response rates for epcoritamab in relapsed/refractory FL?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Dec 2023
Coverage